ClinicalTrials.gg
CompletedNCT02430181LOWR-1Updated Sep 25, 2026Results posted

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

A Phase 2 interventional study of lonafarnib and peginterferon alfa-2a in Chronic Hepatitis D Infection, sponsored by EIT Pharma, Inc.. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by EIT Pharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).

Read the detailed description

Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjects with chronic delta hepatitis will be randomized to receive one of seven different doses of lonafarnib. Dosing will occur over 4-12 weeks, depending on treatment arm, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of seven dose combinations of lonafarnib with and without ritonavir boosting.

02

Conditions studied

  • Chronic Hepatitis D Infection

Browse trials for

03

In context

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

This study's enrollment of 21 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.

Browse Hepatitis D, Chronic studies →

Lead sponsor

EIT Pharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR
  • Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study entry
  • Liver within the last two years
  • Positive viral load by quantitative PCR
  • (ECG) shows no acute ischemia or abnormality and a /QTc interval \<450 milliseconds - using Bazett's correction
  • Females of (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable methods throughout the study:

    1. abstinence
    2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum
    3. IUD in place for at least six months
    4. barrier methods (condom or diaphragm) with spermicide
    5. surgical sterilization of the partner (vasectomy for six months)
    6. hormonal contraceptives for at least three months prior to the first dose of study drug
  • Willing and able to comply with study procedures and provide written

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical trial with or use of any agent within 30 days of Study Visit 1
  • Patients co-infected with
  • Patients with screening tests positive for , or anti-HIV Ab
  • History of decompensated cirrhosis within the past year
  • Active jaundice defined by total > 2.0 excluding Gilbert's disease
  • ≥ 1.5
  • Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (> 20 g per day for females (1.5 standard alcohol drinks) or > 30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL).
  • Drug abuse within the last six months with the exception of cannabinoids and their derivatives
  • Patients with (ANC) \< 1500 cells/mm\^3; count \< 100,000 cells/mm\^3; \< 12 g/dL for women and \< 13 g/dL for men; abnormal TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine concentration ≥ 1.5 times (ULN)
  • History or clinical evidence of any of the following:

    1. variceal bleeding, ascites, hepatic encephalopathy, CTP score > 6, decompensated liver disease or any other form of non-viral hepatitis
    2. immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) requiring more than intermittent nonsteroidal anti-inflammatory medications for management or that requires frequent or prolonged use of (inhaled asthma medications are allowed)
    3. any within 3 years except for basal cell skin cancer
    4. significant or unstable cardiac disease (e.g., angina, congestive heart failure, uncontrolled hypertension, history of arrhythmia)
    5. chronic pulmonary disease (e.g., ) associated with functional impairment
    6. severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization 2
  • Patients with a > 30 kg/m\^2
  • Concomitant drugs known to prolong the
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    lonafarnib - I

    lonafarnib 200 mg BID; n=3

    Drug: lonafarnib

  • Experimental
    lonafarnib - II

    lonafarnib 300 mg BID; n=3

    Drug: lonafarnib

  • Experimental
    lonafarnib - III

    lonafarnib 100 mg TID; n=3

    Drug: lonafarnib

  • Experimental
    lonafarnib/PEG IFN-a - I

    lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3

    Drug: lonafarnib · Drug: peginterferon alfa-2a

  • Experimental
    lonafarnib/PEG IFN-a - II

    lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3

    Drug: lonafarnib · Drug: peginterferon alfa-2a

  • Experimental
    lonafarnib/PEG IFN-a - III

    lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2

    Drug: lonafarnib · Drug: peginterferon alfa-2a

  • Experimental
    lonafarnib/ritonavir

    lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3

    Drug: lonafarnib · Drug: ritonavir

Interventions

  • antiviral farnesyl transferase inhibitor

    Also known as: Sarasar, EBP994

  • immunomodulator

    Also known as: Pegasys, pegylated interferon-alfa, PEG IFN-alfa, PEG IFN-a

  • CYP 3A4 inhibitor, lonafarnib booster

    Also known as: Norvir, RTV

06

What researchers measure

Primary outcomes

  1. Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy

    log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy)

    Time frame: 4-12 weeks

07

Results

Posted Nov 29, 2022

Participant flow

Participant flow — Overall Study
MilestoneLonafarnib - ILonafarnib - IILonafarnib - IIILonafarnib/PEG IFN-a - ILonafarnib/PEG IFN-a - IILonafarnib/PEG IFN-a - IIILonafarnib/Ritonavir
Started3333323
Completed3323300
Not completed0010023

Outcome measures

PrimaryImprovement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy

log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy)

Time frame:
4-12 weeks
Reported as:
Mean · log IU/mL
Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy
log IU/mLLonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/Ritonavir
Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy0.03 (-1.17 to 1.83)-1.78 (-2.28 to -1.46)-1.3 (-1.61 to -0.52)-1.85 (-2.4 to -1.33)0 (0 to 0)0 (0 to 0)-1.2 (-1.41 to -0.91)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lonafarnib 200 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
Lonafarnib 300 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
Lonafarnib 100 mg TID0/3 (0%)1/3 (33.3%)3/3 (100%)
100 mg BID Lonafarnib/PEG IFN-a0/3 (0%)0/3 (0%)3/3 (100%)
200 mg BID Lonafarnib/PEG IFN-a0/3 (0%)0/3 (0%)0/3 (0%)
300 mg BID Lonafarnib/PEG IFN-a0/2 (0%)0/2 (0%)0/2 (0%)
Lonafarnib/Ritonavir0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventLonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/Ritonavir
dehydration secondary to vomiting and diarrheaGastrointestinal disorders0/30/31/30/30/30/20/3
Most frequent other events
Most frequent other events
EventLonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/Ritonavir
weight lossInvestigations3/33/32/31/30/30/22/3
diarrheaGastrointestinal disorders3/33/32/33/30/30/23/3
nauseaGastrointestinal disorders3/33/32/33/30/30/23/3
fatigueGeneral disorders3/32/32/31/30/30/22/3
vomitingGastrointestinal disorders2/33/32/30/30/30/21/3

Baseline characteristics

Patients aged 18-65 years with documented HBsAg, anti-delta positivity for at least 6 months, and compensated liver disease were eligible after evaluation for other forms of chronic liver disease. Patients were required to have detectable HDV-RNA levels at screening, platelet counts \>/= 100,000/mm3, absolute neutrophil count \>/= 1,500 /mm3, and international normalized ratio \<1.5. Patients with hepatocellular carcinoma were excluded.

Age, Continuous
Age, Continuous(years)Lonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/RitonavirTotal
Mean59 (57 to 63)40 (36 to 46)46 (40 to 51)41 (22 to 52)46 (35 to 53)49 (48 to 49)51 (42 to 61)49 (22 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)Lonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/RitonavirTotal
Female21210107
Male121231313
Region of Enrollment
Region of Enrollment(participants)Lonafarnib 200 mg BIDLonafarnib 300 mg BIDLonafarnib 100 mg TID100 mg BID Lonafarnib/PEG IFN-a200 mg BID Lonafarnib/PEG IFN-a300 mg BID Lonafarnib/PEG IFN-aLonafarnib/RitonavirTotal
Turkey333332320
08

Study locations

1 site
  • Ankara University Medical School
    Ankara, Turkey (Türkiye)
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Sep 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2022, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2015
First posted
Apr 30, 2015
Start
Nov 2014
Primary completionActual
Sep 2015
CompletionActual
Nov 2015
Results first posted
Nov 29, 2022
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Eiger BioPharmaceuticals→EIT Pharma, Inc.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Sponsor Eiger BioPharmaceuticals→EIT Pharma, Inc.
    + 3 other changes: identifiers, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02430181
Lead sponsor
EIT Pharma, Inc.
Responsible party
Sponsor
First posted
Apr 30, 2015
Start date
Nov 2014
Primary completion
Sep 2015
Completion
Nov 2015
Results posted
Nov 29, 2022
Last update
Sep 25, 2026

Study contacts

Cihan Yurdaydin, MD
principal investigator · Ankara University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lonafarnib

Start the discussion